Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rania El Botty

Showing results (1-10 of 34) with videos related to

Pageof 4
Sort By:
Annales Pharmaceutiques Francaises|September 30, 2019
Improvement of the anti-proliferative activity of the peptide ERα17p in MCF-7 breast cancer cells using nanodiamondsFrançois Yip, Fariba Nemati, Rania El Botty, et al.
Cancer Letters|March 24, 2025
Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancersMaria M Haykal, Sylvie Rodrigues-Ferreira, Rania El Botty, et al.
Journal of Proteome Research|March 15, 2017
Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer XenograftsLeslie R Euceda, Deborah K Hill, Endre Stokke, et al.
International Journal of Cancer|December 22, 2015
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancersRana Hatem, Dalila Labiod, Sophie Château-Joubert, et al.
Cancer Science|March 9, 2026
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBCCharlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, et al.
International Journal of Cancer|February 5, 2019
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesisWulfran Cacheux, Astrid Lièvre, Sophie Richon, et al.
Frontiers in Oncology|December 12, 2022
<i>In vivo</i> efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenograftsThibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, et al.
Molecular Cell|February 26, 2025
Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumorsDaniele Musiani, Hatice Yücel, Marie Vallette, et al.
Oncotarget|July 25, 2018
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibitionRania El Botty, Florence Coussy, Rana Hatem, et al.
Oncotarget|July 5, 2016
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancersRana Hatem, Rania El Botty, Sophie Chateau-Joubert, et al.
Pageof 4

Showing results (1-10 of 34) with videos related to

Sort By:
Pageof 4
Annales Pharmaceutiques Francaises|September 30, 2019
Improvement of the anti-proliferative activity of the peptide ERα17p in MCF-7 breast cancer cells using nanodiamondsFrançois Yip, Fariba Nemati, Rania El Botty, et al.
Cancer Letters|March 24, 2025
Targeting WEE1 kinase as a therapeutic strategy in ATIP3-deficient breast cancersMaria M Haykal, Sylvie Rodrigues-Ferreira, Rania El Botty, et al.
Journal of Proteome Research|March 15, 2017
Metabolic Response to Everolimus in Patient-Derived Triple-Negative Breast Cancer XenograftsLeslie R Euceda, Deborah K Hill, Endre Stokke, et al.
International Journal of Cancer|December 22, 2015
Vandetanib as a potential new treatment for estrogen receptor-negative breast cancersRana Hatem, Dalila Labiod, Sophie Château-Joubert, et al.
Cancer Science|March 9, 2026
Targeting PRMTs Creates Vulnerability of DNA Double-Stand Break Repair Pathways, and Potentiates Chemotherapy Efficacy in TNBCCharlène Thiebaut, Sébastien Martinez, Ludivine Pruvost, et al.
International Journal of Cancer|February 5, 2019
Interaction between IGF2-PI3K axis and cancer-associated-fibroblasts promotes anal squamous carcinogenesisWulfran Cacheux, Astrid Lièvre, Sophie Richon, et al.
Frontiers in Oncology|December 12, 2022
<i>In vivo</i> efficacy assessment of the CDK4/6 inhibitor palbociclib and the PLK1 inhibitor volasertib in human chordoma xenograftsThibault Passeri, Ahmed Dahmani, Julien Masliah-Planchon, et al.
Molecular Cell|February 26, 2025
Uracil processing by SMUG1 in the absence of UNG triggers homologous recombination and selectively kills BRCA1/2-deficient tumorsDaniele Musiani, Hatice Yücel, Marie Vallette, et al.
Oncotarget|July 25, 2018
Inhibition of mTOR downregulates expression of DNA repair proteins and is highly efficient against BRCA2-mutated breast cancer in combination to PARP inhibitionRania El Botty, Florence Coussy, Rana Hatem, et al.
Oncotarget|July 5, 2016
Targeting mTOR pathway inhibits tumor growth in different molecular subtypes of triple-negative breast cancersRana Hatem, Rania El Botty, Sophie Chateau-Joubert, et al.
Pageof 4